• Lactobacillus acidophilus, DDS-1®
Lactobacillus acidophilus is known to relieve GI discomfort. The DDS-1® bacteria strain modulates intestinal-specific microbiota, short-chain fatty acids and immunological profiles in aging mice. Also, it exhibits superior in-vitro probiotic efficacy when compared to other species, and it provides relief for lactose intolerance.
• Lactobacillus reuteri, UALre-16™
Lactobacillus reuteri strengthens the intestinal barrier and decreases microbial translocation from the gut lumen to the surrounding tissues, supporting normal inflammatory balance. The UALre-16™ bacteria strain supports a balanced microbiome with the production of organic acids, ethanol and reuterin, and it benefits the immune system by influencing cytokine production while promoting regulatory T-cell development and function.
• Bifidobacterium lactis, UABIa-12®
Bifidobacterium lactis improves the metabolic activities of commensal bacteria while helping to relieve a variety of GI discomforts. Human study data demonstrates the UABIa-12® bacteria strain improves abdominal discomfort and severity scores with a corresponding normalization of bowel habits after six weeks.
• Lactobacillus salivarius, UALs-07™
Lactobacillus salivarius demonstrates high survivability in the gut, specifically a high tolerance for stomach acid and bile salts, and it shows antibiotic resistance.The UALs-07™ bacteria strain also has strong adherence potential and demonstrated comparatively excellent adherence to the Caco-2 monolayer, which translates to the ability to adhere to the intestinal wall and helps this strain have lasting effects on immune and digestive health. Additionally, the UALs-07™bacteria strain abundantly produces lactic acid.
• Lactobacillus casei, UALc-03™
Lactobacillus casei has been combined with other probiotic strains of bacteria to assist with regular bowel habits and protect against the effects of unwanted organisms. The UALc-03™ bacteria strain has been shown to be naturally resistant to stomach acid and bile, ensuring its survivability.
• Streptoccocus thermophilus, UASt-09™
Streptoccocus thermophilus upregulates goblet cell activity in colonic epithelial cells to a greater degree than other probiotic strains. The UASt-09™ bacteria strain showed promising potential in refining the mucosal barrier by improving mucus biosynthesis and intestinal immune response under in-vitro conditions.
• Saccharomyces boulardii
Saccharomyces boulardii is a probiotic yeast that was first isolated from the skin of the tropical fruits lychee and mangosteen in 1923 by French scientist Henri Boulard, following the observation that mangosteen consumption controlled occasional diarrhea in natives of Southeast Asia. S. boulardii plays a role in supporting immune defense by increasing levels of sIgA, creating a first line of defense that helps bind and clear harmful bacteria.
